^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SV-102

    i
    Company:
    Syncromune
    Drug class:
    Immunomodulator
    Related drugs:
    1m
    A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=70, Recruiting, Syncromune, Inc. | Phase classification: P1 --> P2 | N=28 --> 70
    Phase classification • Enrollment change
    |
    SV-102
    4ms
    A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=28, Recruiting, Syncromune, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    SV-102
    9ms
    A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castrate-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=28, Not yet recruiting, Syncromune, Inc.
    New P1 trial • Metastases
    |
    SV-102